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 It ’ s a war on kidney fi brosis aft er all. Renal 
fi brosis, characterized by glomeruloscle-
rosis, tubulointerstitial fi brosis, infl am-
matory infiltration, and loss of renal 
parenchyma, is the fi nal common path-
way of progressive kidney disease leading 
to end-stage renal disease. Th e excessive 
accumulation and deposition of extracel-
lular matrix components in the tubu-
lointerstitial compartment contribute to 
the pathogenic process seen in chronic 
kidney disease. Th us, therapeutic meas-
ures to combat tubulointerstitial fi brosis 
by impeding or reversing this pro cess are 
of great potential interest. 
 PPAR-  is one of the three subtypes of 
peroxisome proliferator-activated recep-
tors (PPARs) and is a member of the 
nuclear hormone receptor superfamily. 
Recently, both PPAR-  and -  have been 
implicated in the regulation of infl amma-
tion, fi brosis, and cancer. 1 PPARs ’ role in 
fi brosing diseases has received more atten-
tion in recent years. Th e pharmacological 
activation of PPARs in the kidney has been 
considered a therapeutically suitable strat-
egy against glomerular and tubulointersti-
tial fibrosis. However, there has been 
limited research focusing on the renopro-
tective role of PPAR agonists related to 
their antifi brotic capability. In particular, 
PPAR-  agonists, including the fibrate 
drugs, have shown promise in attenuating 
kidney fi brosis. 2 
 Boor  et al. 3 (this issue) present experi-
mental work suggesting that renal fi brosis 
can be attenuated by a novel PPAR-  -spe-
cifi c agonist, BAY PP1, in models of kid-
ney fi brosis. Th is study is the fi rst of its 
kind to examine any PPAR-  agonist in a 
renal fi brosis model, namely, in the uni-
lateral ureteral obstruction (UUO) and 
the remnant kidney models. Boor  et al. 3 
fi rst clearly demonstrated a correlation 
between PPAR-  expression and renal 
fi brosis. To determine whether BAY PP1 
might have a benefi cial role in renal fail-
ure, they compared it with fenofi brate, 
another commonly used PPAR-  agonist 
with a proven effi  cacy. In the UUO model, 
PPAR-  expression was restored by both 
fenofi brate and BAY PP1, with the latter 
causing a higher increase that was com-
parable to normal levels seen in sham-
opearted animals. 
 In both fi brosis models, localization of 
PPAR-  expression was shown in tubular 
cells with no interstitial source, which is 
consistent, as the authors mention, with 
previously published work. Kidney 
obstruction dramatically decreased 
PPAR-  expression in injured tubules and 
possibly induced interstitial-cell, proba-
bly leukocyte, infi ltration with PPAR-  
expression. Th e antifi brotic eff ects of BAY 
PP1 were explored by examination of cel-
lular and molecular events typically seen 
in renal fi brogenesis. BAY PP1 signifi -
cantly reduced expression of fibrosis 
markers, including transforming growth 
factor-  (TGF-  ), whereas, surprisingly, 
fenofi brate was ineff ective. BAY PP1 did 
not alter infl ammatory-cell infi ltration, 
whereas fenofi brate was associated with 
a signifi cant increase in infi ltrating-cell 
number. Th ese last fi ndings are in direct 
opposition to earlier studies. 4 – 6 Li  et al. 4 
demonstrated attenuating action of fenof-
ibrate on renal infl ammation and tubu-
lointerstitial fibrosis in a diabetic 
nephropathy model. Ansquer  et al. 7 stud-
ied the effect of fenofibrate on kidney 
function in healthy individuals over a 6-
week period and determined possible 
adverse effects on renal function and 
glomerular fi ltration. While tubulointer-
stitial fi brosis is an important feature in 
UUO and infl ammatory processes have 
been recently seen as the important factor 
in the pathogenesis of diabetic nephrop-
athy, the divergent conclusions of these 
studies irrespective of the animal disease 
models are of concern, and more studies 
may be needed to establish a consensus 
on fenofi brate eff ects so that performance 
comparison with BAY PP1 would be 
more appropriate. Finally, unlike fenofi -
brate, BAY PP1 exhibited an antiprolif-
erative effect as determined by lower 
interstitial-cell but not tubular-cell 
number. Th e cells most aff ected by this 
were of fi broblast and pericyte origin, two 
culprits responsible for major collagen 
production. 
 In the UUO model, animals rapidly 
develop, within a few days, severe tubu-
lointerstitial renal fi brosis with an infl am-
matory-cell infiltrate in the affected 
kidney. In contrast, in the remnant kid-
ney model — especially the rat model, 
as was used in this article — renal fi brosis 
develops in 3 months, a more chronic 
model of the development of fibrosis 
that is somewhat closer to what is 
observed in humans. It is important to 
note that, unlike in many studies in which 
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a compound ’ s renoprotective effect is 
evaluated by administration either before 
or at the time of induction of the pathol-
ogy, Boor  et al. 3 initiated their BAY PP1 
treatment before loss of renal function, 
thus mimicking human pathology, in 
which treatment starts only aft er disease 
identifi cation. Th e systemic eff ects of BAY 
PP1 showed no alteration of renal func-
tion or inflammatory response in the 
UUO model, whereas in the remnant 
kidney model BAY PP1 somewhat 
reduced renal dysfunction, although, 
notably, by a slight decrease that was seen 
at a late stage (day   +  50). Reduced renal 
fi brosis and interstitial-cell proliferation 
were also observed in the remnant kidney 
model following treatment with BAY 
PP1, as was similarly observed in the 
UUO model. 
 Th e  in vitro experiments in this paper 
are very enlightening and inspire future 
experiments that investigators should 
pursue. But fi rst, it is important to note 
that the authors demonstrated that BAY 
PP1 did not have a proliferative eff ect on 
kidney fi broblast or tubular cells, which 
is consistent with their  in vivo fi ndings. 
Second, unlike kidney fi broblasts, only 
tubular cells express PPAR-  , which sup-
ports the authors ’ finding of a lack of 
eff ect of BAY PP1 on fi broblasts. Most 
interestingly, conditioned media of cul-
tured BAY PP1-treated tubular cells 
reduced fi broblast proliferation, suggest-
ing possibly a paracrine mechanism of 
action between the cell types. Th is obser-
vation is worth further testing using 
global genome-wide expression profi ling 
(for example, using the Aff ymetrix sys-
tem) to identify molecular and subse-
quent cellular pathways in affected 
fi broblasts, which may mimic the real  in 
vivo setting. In addition, the conditioned 
media of BAY PP1-treated tubular cells 
can be analyzed with protein arrays or 
conditioned-medium arrays to identify 
diff erential protein expression profi les 
induced by BAY PP1 treatment. 
 It is widely accepted that TGF-  and its 
downstream Smad signaling play an 
essential role in tissue fi brosis in general 
and in renal fi brosis in particular. Upreg-
ulation of TGF-  is a universal fi nding in 
virtually every type of chronic kidney 
disease, both in animal models and in 
humans. 8 Boor  et al. 3 show that BAY PP1 
treatment reduced TGF-  expression 
both  in vivo and  in vitro , thereby adding 
more support to its antifi brotic role. In 
contrast to these fi ndings, TGF-  treat-
ment attenuated PPAR-  expression in 
cultured tubular cells, which was restored 
by BAY PP1 supplementation. Th e restor-
ative ability of BAY PP1 to augment 
PPAR-  expression following TGF-  
treatment was also accompanied by 
reduction of fi broblast markers, indicat-
ing that the eff ect of BAY PP1 on tubular 
cells not only includes stabilization of 
epithelial phenotype but, more excitingly, 
extends to reducing extracellular matrix 
production and cytokine factors that play 
a key role in fi brogenic cell activation. In 
this context, it would be worthwhile to 
perform more studies to unravel addi-
tional mechanisms of inhibition of TGF-
   signaling by BAY PP1 and their 
implications for the contribution of epi-
thelial – mesenchymal transdiff erentiation 
to kidney fi brosis. 
 Boor  et al. mention in their paper some 
interesting unpublished fi ndings regard-
ing fenofi brate and BAY PP1 distribution. 
Th ey claim that whereas fenofi brate accu-
mulates in the liver, BAY PP1 has a nice 
balanced distribution, which may account 
for the better effi  cacy of BAY PP1 in the 
kidney. However, this raises the question 
of whether BAY PP1 ’ s structure, and its 
cellular and molecular eff ects, are the key 
players in its performance or whether it 
is related more to its better distribution 
and renal access in comparison with 
fenofi brate. More understanding of the 
pharmacokinetics is needed to better 
interpret the eff ects of BAY PP1. Regard-
less of this issue, Boor  et al. 3 clearly dem-
onstrate that the compound had a 
benefi cial antifi brotic eff ect, although the 
mechanism responsible for this effect 
remains poorly understood. 
 Some additional comments regarding 
the study by Boor  et al. 3 are worth con-
sidering. First, it would be worthwhile to 
compare PPAR-  expression in human 
kidney tissue with obstructive nephro-
pathy versus control normal kidney 
 Table 1  |  Summary of renoprotective eff ects of BAY PP1 and fenofi brate in diff erent animal and  in vitro models of kidney 
disease 
 Parameter  Fenofi brate treatment  BAY PP1 treatment 
  Unilateral ureteral obstruction 
 Model  Wild type 
 PPAR   – / –   
knockout  Remnant kidney 
 In vitro  cultured 
tubular cells 
 In vitro  cultured 
fi broblast cells 
 Antifi brotic  Ineff ective  Eff ectively 
reduced ( ↓ ~ 50 % ) 
 Ineff ective  Eff ectively reduced 
( ↓ ~ 30 % ) 
 Eff ectively 
reduced ( ↓ ~ 30 % ) 
 Ineff ective 
 Antiproliferative  Ineff ective  Eff ectively 
reduced ( ↓ ~ 45 % ) 
 Not determined  Eff ectively reduced 
( ↓ ~ 25 % ) 
 Ineff ective  Ineff ective 
 Anti-infl ammatory  Eff ectively 
increased ( ↑ ~ 20 % ) 
 Ineff ective  Ineff ective  Ineff ective  Not determined  Not determined 
 Antiapoptotic  Not determined  Not determined  Not determined  Ineff ective  Ineff ective  Not determined 
 Renal function  Ineff ective  Ineff ective  Not determined  Eff ectively reduced 
( ↓ ~ 20 % ) 
 Not determined  Not determined 
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tissue. In humans, chronic and acute 
ureteral obstruction can occur in vari-
ous clinical situations, such as ureteral 
stone or ureteral carcinoma. Most pub-
lished work examined PPAR-  levels in 
cell-line models, but none correlated 
PPAR-  levels in kidney tissue from 
patients with chronic obstructive neph-
ropathy at various stages of develop-
ment. Second, it is interesting that Boor 
 et al. 3 discovered no signifi cant diff er-
ences in renal fi brosis between PPAR-  -
deficient (PPAR-   – / –  ) and wild-type 
animals. Although the authors offer 
some reasonable explanations, these 
remain unsatisfying to explain the ben-
efi t of BAY PP1 therapy in chronic kid-
ney disease, of which renal fi brosis is a 
major manifestation. It also raises the 
possibility that BAY PP1 may act partly 
through PPAR-independent pathways, 
depending on the model used, as has 
similarly been seen with other PPAR-  
agonists. 9 Park  et al. 10 induced diabetes 
in PPAR-  knockout mice and found 
increased profi brotic and proinfl amma-
tory eff ects; thus, more experiments with 
BAY PP1 might be needed in PPAR-  
knockout animals, but with modi-
fications to experimental conditions. 
Th ird, it would be interesting to conduct 
a time-course analysis in UUO models 
to determine possibly early progressive 
onset of PPAR-  expression. 
 In conclusion, the findings of Boor 
 et al. 3 (summarized in  Table 1 ) represent 
exciting work on a novel PPAR-  agonist, 
BAP PP1, that is potentially capable of 
ameliorating renal fi brosis and improving 
renal function. It would be unfair to com-
pare the perfor mance of BAY PP1 to that 
of other currently available PPAR-  ago-
nists, as more research is needed for this 
assessment. Indeed, future studies should 
examine BAY PP1 ’ s safety and effi  cacy, 
as well as its molecular and cellular inter-
actions. So, this Jedi needs to be curbed 
before it is ready to intervene against 
renal fi brosis. 
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 Old friends form alliance 
against podocytes 
 Matias  Simons 1 , 2 , 3 and  Tobias B.  Huber 2 , 4 
 Wang and colleagues identify the activation of Wnt signaling as an 
important downstream event in transforming growth factor-  -
mediated podocyte injury. Supported by other recent studies, canonical 
Wnt signaling is emerging as a critical stress pathway in podocytes and 
may be exploited for therapeutic strategies in the treatment of 
glomerulopathies. 
 Kidney International (2011)  80, 1117 – 1119.  doi: 10.1038/ki.2011.298 
 Animal development and homeostasis 
require a set of highly conserved cell-sig-
naling pathways (including Wnt, trans-
forming growth factor-  , Hedgehog, 
receptor tyrosine kinase (RTK), Notch, 
JAK / STAT, and mTOR) that are used 
repeatedly in diff erent spatial and tempo-
ral contexts. In recent years, research has 
also focused on the cross-talk among 
these major signaling pathways. Th e cross-
talk between the transforming growth 
factor-  (TGF-  ) / bone morphogenetic 
protein (BMP) and Wnt pathways is prob-
ably the most extensively studied. Th e two 
pathways show strong interactions 
throughout the life of an animal, also on 
the molecular level. TGF-  / BMP and Wnt 
proteins are secreted ligands that form 
overlapping extracellular gradients during 
embryonic development. In the  Drosophila 
wing disc, for example, the concerted 
action of orthogonal gradients of Wg and 
a member of the TGF-  family of secreted 
factors, Decapentaplegic (Dpp), deter-
mines the shape of the wing. Also in the 
responding cells, a number of  cytoplasmic 
interactions between components of these 
pathways fi ne-tune their respective signal-
ing. Th e hot spot of TGF-  / Wnt cross-
talk, however, is the nucleus.   -catenin 
and Lef1 / Tcf, which are downstream 
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